IMRX

Immuneering's stock experienced a 19% jump in late December 2025. In March 2026, positive Phase 2a trial data for atebimetinib in pancreatic cancer led to gains of 7.03% on March 6 and 24% on March 5, with 64% overall survival at 12 months. The company announced FDA and EMA alignment on its Phase 3 MAPKeeper 301 trial design. Immuneering presented data at the AACR Annual Meeting and participated in the Needham Virtual Healthcare Conference. Updated Phase 2a data was presented at the ASCO Annual Meeting. The Q4 2025 earnings report and positive Phase 2a survival data contributed to a positive market reaction, and analysts maintained a "Buy" rating as of May 2026.